IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders.
about
The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort.IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients.
P2860
IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
IL28B genotype predicts respon ...... partial- and null-responders.
@ast
IL28B genotype predicts respon ...... partial- and null-responders.
@en
type
label
IL28B genotype predicts respon ...... partial- and null-responders.
@ast
IL28B genotype predicts respon ...... partial- and null-responders.
@en
prefLabel
IL28B genotype predicts respon ...... partial- and null-responders.
@ast
IL28B genotype predicts respon ...... partial- and null-responders.
@en
P2093
P2860
P1433
P1476
IL28B genotype predicts respon ...... partial- and null-responders.
@en
P2093
Adele McCormick
Amanda Tavares
Geoffrey Dusheiko
Giorgio Calisti
Malcolm J Macartney
Michael Jacobs
Tanzina Haque
Wendy Labbett
P2860
P2888
P356
10.1186/S40064-015-1137-X
P577
2015-07-16T00:00:00Z
P5875
P6179
1046524983